News Releases

Date Title and Summary View
June 4, 2019
– KVD900 Demonstrates Rapid and Nearly Complete Suppression of Plasma Kallikrein Activity in a Phase 1 Study – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 4, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
Additional Formats
May 30, 2019
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 30, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...
Additional Formats
May 28, 2019
– KVD900 Phase 1 Data Show Rapid Suppression of Plasma Kallikrein Activity and is Well Tolerated for Potential Use as On-Demand Treatment for HAE – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 28, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical...
Additional Formats
May 20, 2019
– Phase 1 Data on Oral Plasma Kallikrein Inhibitor KVD900 for Potential On-Demand Treatment of HAE Attacks to be Presented – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 20, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the...
Additional Formats
April 30, 2019
– Novel Oral Plasma Kallikrein Inhibitors KV998052 and KV998054 Prevent and Reverse VEGF-Induced Retinal Edema in Mice – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 30, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the...
Additional Formats
April 22, 2019
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 22, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Daniel Soland has...
Additional Formats
April 3, 2019
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 3, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...
Additional Formats
March 27, 2019
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 27, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the promotion of Ben...
Additional Formats
March 14, 2019
– Oral Hereditary Angioedema (HAE) Candidate KVD900 Phase 2 Trial Progressing – – Intravitreal Diabetic Macular Edema (DME) Candidate KVD001 Phase 2 Trial Completion Expected H2 2019 – – Oral Plasma Kallikrein Inhibitor Candidate KVD824 Dosing in First-in-Human Trial – CAMBRIDGE, Mass....
Additional Formats
February 25, 2019
– KVD900 600 mg Provides >90% Inhibition of Plasma Kallikrein Within 30 Minutes of Dosing – – Single 600 mg Dose of KVD900 Provides Protection of HK Cleavage for at Least 10 Hours – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 25, 2019-- KalVista Pharmaceuticals, Inc....
Additional Formats
Displaying 1 - 10 of 12